Insider Buying: Pathfinder Bancorp (NASDAQ:PBHC) CEO Purchases 1,400 Shares of Stock

Pathfinder Bancorp CEO James Dowd bought 1,400 shares of PBHC on June 2 at an average $13.69 each, for $19,166, according to an SEC filing. After the purchase, he directly owned 19,452 shares. PBHC traded up 1.5% to $13.86. The company reported Q1 EPS of $0.38 on revenue of $11.49M and paid a $0.10 quarterly dividend.

Original reporting
Published Jun 4, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Insider Buying: Pathfinder Bancorp (NASDAQ:PBHC) CEO Purchases 1,400 Shares of Stock — source image
Decision brief

The 30-second read

$PBHCBullishMed
01

Why it matters

The immediate tradable element is the disclosed insider accumulation, which can influence short-term sentiment and positioning. However, the article does not introduce new earnings guidance, credit events, or regulatory actions that would materially reprice the bank’s risk.

02

Market read

PBHC receives a modest bullish sentiment input from insider buying, but fundamentals remain soft (negative ROE/net margin) and analyst stance is still Sell.

03

What to watch

The article also notes negative ROE/net margin and a reaffirmed Sell rating; without changes in asset quality or guidance, the insider signal may fade.

Relevance 6/10Novelty 7/10Timing: After-hours/next-session positioning following the June 2 insider buy disclosure

Background

The piece summarizes an SEC-disclosed insider purchase (CEO buying shares) and includes recent fundamentals (last quarterly EPS, dividend, and valuation/technical levels).

Company-level read

Ticker impact

$PBHCBullishMedium confidence
Context

PBHC CEO James Dowd bought 1,400 shares at $13.69, increasing his stake by 7.76%, disclosed via SEC filing.

Expected impact

Likely modest, short-lived support to the stock; follow-through depends on upcoming earnings/credit-quality signals.

Evidence & confidence

The article provides a concrete Form 4-style buy and the stock’s current trading context, but no new guidance, asset/liability change, or regulatory/credit event.

Market effects

For small regional/savings banks, insider buys can slightly improve perceived confidence, but they rarely override credit-cycle risks.

Limited to local community-bank sentiment; no broader regional shock is described.

Minimal; this is company-specific ownership activity.

Counterpoint

The buy may be routine compensation/portfolio rebalancing rather than a strong forward-looking signal, especially given the modest $19k trade size.

Key entities

  • Pathfinder Bancorp, Inc.

    NASDAQ-listed savings & loans company; subject of the CEO insider purchase disclosure.

  • James Dowd

    CEO who purchased 1,400 PBHC shares at an average $13.69.

Related articles

$PBHCMed

Prosperity Bancshares, Inc. Q2 2026 Earnings Call Summary

Strategic Integration and Performance Drivers Management successfully closed the Stellar Bancorp merger on July 1, 2026, adding 52 banking offices and significantly expanding the Houston and East Texas footprint. Core net income growth of 20.4% year-over-year was driven by the repricing of assets and the successful inclusion of American Bank and Texas Partners Bank results.

$PBHCMed

Pathfinder Bancorp, Inc. (PBHC): Results of Operations and Financial Condition

Pathfinder Bancorp, Inc. (PBHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Investor/Media Contacts James A. Dowd, President, CEO Justin K. Bigham, Executive Vice President, CFO Telephone: (315) 343-0057 Pathfinder Bancorp, Inc. Announces Financial Results for the Second Quarter of 2026 Pathfinder grew earnings to $0.42 per share in the second quarter of

$NXEMed

Is BHP Group (BHP) the Missing Piece in NexGen Energy (NXE)’s $1 Billion Financing Plan?

NexGen Energy (NXE) is in talks with BHP Group (BHP) for a potential equity stake and financing for its Rook I uranium project. NexGen aims to raise $1 billion over nine months. BHP reported strong financials, with $33 billion in EBITDA and $9.8 billion in free cash flow. NexGen has no revenue but holds $970.25 million in cash. Investors should watch for a formal partnership between the two.

$AZNMed

13 clinical candidates revealed in Chicago

At the American Chemical Society Fall 2026 meeting, 13 new drug candidates were unveiled by various companies, targeting diseases like cancer, lupus, and acne. Presenters included Quanta Therapeutics, AstraZeneca, Novartis, and Pfizer, among others, discussing their drug discovery strategies and clinical trials.